Full Text
Full Text PDF
Abstract
Atypical antipsychotics is known to cause a number of adverse metabolic effects, including weight gain, insulin resistance, hyperglycemia, dyslipidemia and type 2 diabetes mellitus. Aripiprazole is an new atypical antipsychotic that has a safer profile compared to other antipsychotic medications with regard to its effect on weight gain, glucose tolerance and prolactin level. However, recently there have been few case reports on hiperglisemia and diabetic ketoacidosis related by aripiprazole. In this report, we discuss a clinical case with tip 1 diabetes mellitus that developed hiperglisemia during aripiprazole treatment.
Similar Articles
Article Info
Published In
Journal
Neuropsychiatric Investigation
Volume / Issue
Volume 53 · Issue 4
Pages
33-36
History
Published Online
May 1, 2015
Copyright
Copyright (c) 2015 Neuropsychiatric Investigation
Affiliations
Mustafa Küçükköse
Bürge Kabukçu Başay
Cite this Article
Küçükköse, M., & Başay, B. K. (2015). Aripiprazole Induced Hyperglycemia in A Child With Tip 1 Diabetes Mellitus: A Case Report. Neuropsychiatric Investigation, 53(4), 33–36. https://doi.org/10.5455/NYS.20160324080718
Outlines